Abstract
Both stem cells and cancer cells can proliferate indefinitely. In many case, cancers consist of the cells expressing tissue-specific stem cell markers and the cells expressing differentiation markers. Moreover, it has been revealed that many cancer cells express ATP-binding cassette (ABC) transporters, by which the cells pump out a specific fluorescence dyes as well as anti-cancer drugs. Thus these finding suggest that either cancer cells resemble stem cells or cancers contain stem cell-like cells. Using the common characteristics between brain cancer cells and neural stem cells, several research groups have succeeded to identify stem cell-like brain cancer cells (called “brain cancer stem cells”) in brain tumors and brain cancer cell lines. The brain cancer stem cells, but not the other cancer cells, self-renew, form tumors when transplanted in vivo, and are highly resistant for both anti-cancer drugs and irradiation. Together all, these recent progresses suggest that it is crucial to characterize brain cancer stem cells and identify targets for the therapy.
Keywords: Cancer stem cells (CSCs), CD133, side population (SP), cell of origin, neural stem cells (NSCs)
Current Cancer Therapy Reviews
Title: Stem Cell-Like Brain Cancer Cells
Volume: 4 Issue: 3
Author(s): Toru Kondo
Affiliation:
Keywords: Cancer stem cells (CSCs), CD133, side population (SP), cell of origin, neural stem cells (NSCs)
Abstract: Both stem cells and cancer cells can proliferate indefinitely. In many case, cancers consist of the cells expressing tissue-specific stem cell markers and the cells expressing differentiation markers. Moreover, it has been revealed that many cancer cells express ATP-binding cassette (ABC) transporters, by which the cells pump out a specific fluorescence dyes as well as anti-cancer drugs. Thus these finding suggest that either cancer cells resemble stem cells or cancers contain stem cell-like cells. Using the common characteristics between brain cancer cells and neural stem cells, several research groups have succeeded to identify stem cell-like brain cancer cells (called “brain cancer stem cells”) in brain tumors and brain cancer cell lines. The brain cancer stem cells, but not the other cancer cells, self-renew, form tumors when transplanted in vivo, and are highly resistant for both anti-cancer drugs and irradiation. Together all, these recent progresses suggest that it is crucial to characterize brain cancer stem cells and identify targets for the therapy.
Export Options
About this article
Cite this article as:
Kondo Toru, Stem Cell-Like Brain Cancer Cells, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294258
DOI https://dx.doi.org/10.2174/157339408785294258 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Anti-Cancer Approach with NK4: Bivalent Action and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry Mesenchymal stem cell therapy for inflammatory bowel diseases: promise and challenge
Current Stem Cell Research & Therapy Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology Electrochemical Cell-based Biosensors for Biomedical Applications
Current Topics in Medicinal Chemistry Innate Immune Receptors and IRF Family Transcription Factors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Glioblastoma Therapy – Part I (Guest Editor: Hui-Wen Lo)]
Anti-Cancer Agents in Medicinal Chemistry DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Combinatorial Approaches for the Identification of Brain Drug Delivery Targets
Current Pharmaceutical Design Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry G-Protein Signaling, Lipid Rafts and the Possible Sites of Action for the Antidepressant Effects of n-3 Polyunsaturated Fatty Acids
CNS & Neurological Disorders - Drug Targets Thrombospondins as Anti-Angiogenic Therapeutic Agents
Current Pharmaceutical Design Regulation of Radiation-Induced Apoptosis by Early Growth Response-1 Gene in Solid Tumors
Current Cancer Drug Targets Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Do We have a Satisfactory Cell Viability Assay? Review of the Currently Commercially-Available Assays
Current Drug Discovery Technologies